The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor

Cited by papers we hold 8

• Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions · 2022
  Corrected
• Selective Targeting of TNF Receptors as a Novel Therapeutic Approach · 2020
  No notice
• Unleashing endogenous TNF-alpha as a cancer immunotherapeutic · 2018
  No notice
• Post-stroke inflammation—target or tool for therapy? · 2018
  No notice
• Investigating the Role of TNF-α and IFN-γ Activation on the Dynamics of iNOS Gene Expression in LPS Stimulated Macrophages · 2016
  No notice
• TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine · 2013
  No notice
• Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease · 2012
  No notice
• TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease · 2008
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.